CA3094307A1 - Methods for treating melanoma - Google Patents
Methods for treating melanoma Download PDFInfo
- Publication number
- CA3094307A1 CA3094307A1 CA3094307A CA3094307A CA3094307A1 CA 3094307 A1 CA3094307 A1 CA 3094307A1 CA 3094307 A CA3094307 A CA 3094307A CA 3094307 A CA3094307 A CA 3094307A CA 3094307 A1 CA3094307 A1 CA 3094307A1
- Authority
- CA
- Canada
- Prior art keywords
- melanoma
- tumor
- dapansutrile
- cells
- diet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862645999P | 2018-03-21 | 2018-03-21 | |
| US62/645,999 | 2018-03-21 | ||
| PCT/US2019/022770 WO2019182981A1 (en) | 2018-03-21 | 2019-03-18 | Methods for treating melanoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3094307A1 true CA3094307A1 (en) | 2019-09-26 |
Family
ID=67987925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3094307A Pending CA3094307A1 (en) | 2018-03-21 | 2019-03-18 | Methods for treating melanoma |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11857529B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3768384B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7229565B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111867678B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3094307A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020009552A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019182981A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12121565B2 (en) * | 2019-09-13 | 2024-10-22 | Duke University | Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies |
| EP4045009A4 (en) * | 2019-10-14 | 2023-11-01 | Olatec Therapeutics LLC | METHOD FOR TREATING BREAST CANCER |
| EP4387729A4 (en) * | 2021-08-19 | 2025-07-09 | Olatec Therapeutics Inc | METHODS OF TREATMENT OF PARKINSON'S DISEASE |
| WO2026035767A1 (en) * | 2024-08-06 | 2026-02-12 | Olatec Therapeutics, Inc. | Methods for treating melanoma metastasis to liver and lungs |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013006708A (es) * | 2010-12-15 | 2013-09-13 | Olatec Ind Llc | Composicion de 3-metanosulfonilpropionitrilo para el tratamiento de la inflamacion y el dolor. |
| CA2875053C (en) * | 2012-06-05 | 2020-07-14 | Olatec Industries Llc | Pharmaceutical composition for treating inflammation and pain |
| JP6185575B2 (ja) * | 2012-06-05 | 2017-08-23 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | 皮膚炎症性疾患の治療方法 |
| JP6929792B2 (ja) * | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| EP3288980B1 (en) * | 2015-04-28 | 2021-03-10 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| EP3445761A1 (en) * | 2016-04-19 | 2019-02-27 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| ES2970485T3 (es) * | 2017-01-06 | 2024-05-29 | Olatec Therapeutics Llc | Composición farmacéutica para su uso en el tratamiento de enfermedades cardiovasculares |
| EP3589370A4 (en) * | 2017-01-06 | 2020-11-18 | Olatec Therapeutics LLC | MULTIPLE SCLEROSIS TREATMENT METHOD |
| US20210254056A1 (en) | 2017-05-05 | 2021-08-19 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
| WO2019152627A1 (en) * | 2018-01-31 | 2019-08-08 | Olatec Therapeutics Llc | Method for preventing or treating alzheimer's disease |
-
2019
- 2019-03-18 JP JP2020550082A patent/JP7229565B2/ja active Active
- 2019-03-18 CN CN201980020523.3A patent/CN111867678B/zh active Active
- 2019-03-18 WO PCT/US2019/022770 patent/WO2019182981A1/en not_active Ceased
- 2019-03-18 CA CA3094307A patent/CA3094307A1/en active Pending
- 2019-03-18 EP EP19771591.5A patent/EP3768384B1/en active Active
- 2019-03-18 MX MX2020009552A patent/MX2020009552A/es unknown
-
2020
- 2020-09-15 US US17/021,733 patent/US11857529B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021518374A (ja) | 2021-08-02 |
| WO2019182981A1 (en) | 2019-09-26 |
| JP7229565B2 (ja) | 2023-02-28 |
| CN111867678A (zh) | 2020-10-30 |
| EP3768384A4 (en) | 2021-11-17 |
| EP3768384B1 (en) | 2025-06-25 |
| US20200405681A1 (en) | 2020-12-31 |
| EP3768384A1 (en) | 2021-01-27 |
| MX2020009552A (es) | 2020-10-05 |
| US11857529B2 (en) | 2024-01-02 |
| CN111867678B (zh) | 2023-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11857529B2 (en) | Methods for treating melanoma | |
| US20130022609A1 (en) | Method of treating androgen independent prostate cancer | |
| JP6963545B2 (ja) | 癌を治療するための併用療法 | |
| JP2020520921A (ja) | 癌を処置する併用療法 | |
| CN108139403B (zh) | 用于组合疗法的患者的选择 | |
| US12582628B2 (en) | Methods for treating breast cancer | |
| US11517575B2 (en) | Use of minaprine to reduce tumor growth | |
| JP2011506436A (ja) | 細胞傷害性tリンパ球抗原4(ctla4)に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| KR20090020646A (ko) | 4기 악성 흑색종의 치료를 위한 약제의 제조를 위한 티모신알파 1의 용도 | |
| EP3664786B1 (en) | Method for treating schnitzler's syndrome | |
| US20240417812A1 (en) | Methods for treating solid cancer patients with clonal hematopoiesis of indeterminate potential | |
| US20240358669A1 (en) | Methods for treating pancreatic cancer | |
| WO2026035767A1 (en) | Methods for treating melanoma metastasis to liver and lungs | |
| Arshad | 68P Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ER+ breast cancer | |
| US20170224683A1 (en) | Treatment of melanoma by blocking benzamil sensitive ion channels/exchangers | |
| HK40096805A (en) | Selection of patients for combination therapy | |
| WO2025021587A1 (en) | Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof | |
| KR20200124661A (ko) | 종양 성장을 감소시키기 위한 미나프린의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231222 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250128 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - SMALL Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250310 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250310 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250310 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250514 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250516 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250722 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250722 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - SMALL Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260309 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260309 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260511 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260511 |